Phase II clinical trial of metronomic oral capecitabine therapy combined with aromatase inhibitors in postmenopausal metastatic and recurrent breast cancer resistant to first-line aromatase inhibitors
机构：[1]Department of Breast Surgery, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, ShangHai, China[2]Department of Breast Surgery, The First People’s Hospital of Kunming, Kunming, Yunnan, 650032, China, Kunming, China[3]Department of Medical Oncology, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, shanghai, China
第一作者机构：[1]Department of Breast Surgery, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, ShangHai, China
推荐引用方式(GB/T 7714)：
Jian-wei L.,Xiao-qing J.,Li L.,et al.Phase II clinical trial of metronomic oral capecitabine therapy combined with aromatase inhibitors in postmenopausal metastatic and recurrent breast cancer resistant to first-line aromatase inhibitors[J].EUROPEAN JOURNAL OF CANCER.2015,51:S281-S281.doi:10.1016/S0959-8049(16)30798-5.
APA：
Jian-wei, L.,Xiao-qing, J.,Li, L.,Yu-jie, W.,Zhi-min, S....&Guang-yu, L..(2015).Phase II clinical trial of metronomic oral capecitabine therapy combined with aromatase inhibitors in postmenopausal metastatic and recurrent breast cancer resistant to first-line aromatase inhibitors.EUROPEAN JOURNAL OF CANCER,51,
MLA：
Jian-wei, L.,et al."Phase II clinical trial of metronomic oral capecitabine therapy combined with aromatase inhibitors in postmenopausal metastatic and recurrent breast cancer resistant to first-line aromatase inhibitors".EUROPEAN JOURNAL OF CANCER 51.(2015):S281-S281
医学